Effects of Transplanted Umbilical Cord Blood Mononuclear Cells Overexpressing GDNF on Spatial Memory and Hippocampal Synaptic Proteins in a Mouse Model of Alzheimer’s Disease
Restricted accessResearch articleFirst published online May 21, 2019
Effects of Transplanted Umbilical Cord Blood Mononuclear Cells Overexpressing GDNF on Spatial Memory and Hippocampal Synaptic Proteins in a Mouse Model of Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive incurable neurodegenerative disorder. Glial cell line-derived neurotrophic factor (GDNF) is a prominent regulator of brain tissue and has an impressive potential for use in AD therapy. While its metabolism is still not fully understood, delivering neuropeptides such as GDNF via umbilical cord blood mononuclear cells (UCBMCs) to the sites of neurodegeneration is a promising approach in the development of innovative therapeutic avenues.
Methods:
UCBMCs were transduced with adenoviral vectors expressing GDNF and injected into AD transgenic mice. Various parameters including homing and survival of transplanted cells, expression of GDNF and synaptic proteins, as well as spatial memory were evaluated.
Results:
UCBMCs were observed in the hippocampus and cortex several weeks after transplantation, and their long-term presence was associated with improved spatial memory. Post-synaptic density protein 95 (PSD-95) and synaptophysin levels in the hippocampus were also effectively restored following the procedure in AD mice.
Conclusions:
Our data indicate that gene-cell therapy with GDNF-overexpressing UCBMCs may produce long-lasting neuroprotection and stimulation of synaptogenesis. Such adenoviral constructs could potentially possess a high therapeutic potential for the treatment of AD.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
2.
ScheffSW, PriceDA, SchmittFA, DeKoskyST, MufsonEJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology68, 1501–1508.
3.
SelkoeDJ (2002) Alzheimer’s disease is a synaptic failure. Science298, 789–791.
4.
SivanesanS, TanA, RajadasJ (2013) Pathogenesis of Abeta oligomers in synaptic failure. Curr Alzheimer Res10, 316–323.
5.
FornerS, Baglietto-VargasD, MartiniAC, Trujillo-EstradaL, LaFerlaFM (2017) Synaptic impairment in Alzheimer’s disease: A dysregulated symphony. Trends Neurosci40, 347–357.
6.
MukhamedyarovMA, ZefirovAL (2013) [The influence of beta-amyloid peptide on the functions of excitable tissues: Physiological and pathological aspects]. Usp Fiziol Nauk44, 55–71.
7.
BudniJ, Bellettini-SantosT, MinaF, GarcezML, ZugnoAI (2015) The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis6, 331–341.
8.
IbanezCF, AndressooJO (2017) Biology of GDNF and its receptors - Relevance for disorders of the central nervous system. Neurobiol Dis97, 80–89.
9.
AiravaaraM, PletnikovaO, DoyleME, ZhangYE, TroncosoJC, LiuQR (2011) Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J Biol Chem286, 45093–45102.
10.
RevillaS, SunolC, Garcia-MesaY, Gimenez-LlortL, SanfeliuC, CristofolR (2014) Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neuropharmacology81, 55–63.
11.
ForlenzaOV, MirandaAS, GuimarI, TalibLL, DinizBS, GattazWF, TeixeiraAL (2015) Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimers Dis46, 423–429.
12.
StratenG, SaurR, LaskeC, GasserT, AnnasP, BasunH, LeyheT (2011) Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease. Curr Alzheimer Res8, 853–859.
13.
IslamovRR, RizvanovAA, FedotovaVY, IzmailovAA, SafiullovZZ, GaraninaEE, SalafutdinovII, SokolovME, MukhamedyarovMA, PalotásA (2017) Tandem delivery of multiple therapeutic genes using umbilical cord blood cells improves symptomatic outcomes in ALS. Mol Neurobiol54, 4756–4763.
14.
IslamovRR, RizvanovAA, MukhamedyarovMA, SalafutdinovII, GaraninaEE, FedotovaVY, SolovyevaVV, MukhamedshinaYO, SafiullovZZ, IzmailovAA, GusevaDS, ZefirovAL, KiyasovAP, PalotásA (2015) Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule. Curr Gene Ther15, 266–276.
15.
MukhamedyarovMA, LeushinaAV, TikhonovaAE, PetukhovaEO, GaraninaEE, Ben TalebR, KaliginMS, MukhamedshinaYO, RizvanovAA, ZefirovAL, IslamovRR (2018) Intravenous transplantation of human umbilical cord blood mononuclear cells overexpressing nerve growth factor improves spatial memory in APP/PS1 transgenic mice with a model of Alzheimer’s disease. Bionanoscience8, 473–480.
16.
PetukhovaEO, MukhamedshinaYO, VasilievaOY, AksenovaLY, SolovyevaVV, GaraninaEE, RizvanovAA, ZefirovAL, IslamovRR, MukhamedyarovMA (2015) Stimulation of neurogenesis at hippocampus in Alzheimer’s disease. Genes Cells10, 54–59.
17.
MukhamedshinaYO, ShaymardanovaGF, GaraninaEE, SalafutdinovII, RizvanovAA, IslamovRR, ChelyshevYA (2016) Adenoviral vector carrying glial cell-derived neurotrophic factor for direct gene therapy in comparison with human umbilical cord blood cell-mediated therapy of spinal cord injury in rat. Spinal Cord54, 347–359.
18.
MukhamedshinaYO, ShaymardanovaGF, MukhitovAR, GaraninaEE, RizvanovAA, ChelyshevYA (2014) Phenotypic modifications and quantitative analysis of glial cells in the area of spinal cord injury at the cell-mediated and direct gene delivery gdnf. Genes Cells9, 217–222.
19.
HawleyTS, HerbertDJ, EakerSS, HawleyRG (2004) Multiparameter flow cytometry of fluorescent protein reporters. Methods Mol Biol263, 219–238.
20.
DeaconRM, RawlinsJN (2006) T-maze alternation in the rodent. Nat Protoc1, 7–12.
21.
CalhounME, JuckerM, MartinLJ, ThinakaranG, PriceDL, MoutonPR (1996) Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol25, 821–828.
HuntCA, SchenkerLJ, KennedyMB (1996) PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. J Neurosci16, 1380–1388.
25.
MigaudM, CharlesworthP, DempsterM, WebsterLC, WatabeAM, MakhinsonM, HeY, RamsayMF, MorrisRG, MorrisonJH, O’DellTJ, GrantSG (1998) Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature396, 433–439.
26.
AllenSJ, WatsonJJ, ShoemarkDK, BaruaNU, PatelNK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther138, 155–175.
27.
PertusaM, Garcia-MatasS, MammeriH, AdellA, RodrigoT, MalletJ, CristofolR, SarkisC, SanfeliuC (2008) Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging29, 1366–1379.
28.
ChengH, FuYS, GuoJW (2004) Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus14, 77–86.
29.
ProctorDT, CoulsonEJ, DoddPR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis21, 795–811.
30.
SzeCI, TroncosoJC, KawasC, MoutonP, PriceDL, MartinLJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol56, 933–944.
31.
Garbuzova-DavisS, WillingAE, ZigovaT, SaportaS, JustenEB, LaneJC, HudsonJE, ChenN, DavisCD, SanbergPR (2003) Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: Distribution, migration, and differentiation. J Hematother Stem Cell Res12, 255–270.
32.
PasswegJR, BaldomeroH, BregniM, CesaroS, DregerP, DuarteRF, FalkenburgJH, KrogerN, Farge-BancelD, GasparHB, MarshJ, MohtyM, PetersC, SuredaA, VelardiA, Ruiz de ElviraC, MadrigalA, European Group for Blood and Marrow Transplantation (2013) Hematopoietic SCT in Europe: Data and trends in 2011. Bone Marrow Transplant48, 1161–1167.
